Pivekimab Sunirine-pvzy Clinical Summary

December 10, 2026

Thursday, December 10, 2026 at 12:00 PM–1:00 PM EST                        Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Blastic plasmacytoid dendritic cell neoplasm or BPDCN is a rare and aggressive hematologic malignancy associated with high mortality and poor survival outcomes. The disease most commonly affects older adults, with a median age at diagnosis in the mid-60s and allogeneic hematopoietic stem cell transplantation in first remission offers the best chance for durable survival but is only feasible for a minority of patients. Although targeted therapies have been introduced for BPDCN, treatment options remain limited, with significant unmet need, particularly for patients who are older, have prior or concomitant hematologic malignancy, or have relapsed/refractory disease.

PVEK is a CD123-directed antibody and alkylating agent conjugate indicated for the treatment of adult patients with BPDCN. In the CADENZA study, PVEK demonstrated clinical activity in treatment naïve and relapsed/refractory BPDCN patients. Key safety considerations for PVEK include hepatotoxicity and veno-occlusive disease (VOD), as well as infusion-related reactions and edema. PVEK carries a Boxed Warning for hepatotoxicity, including hepatic VOD, which has been reported and can be severe or fatal. Patients should be monitored closely for signs and symptoms of VOD.

Learning Objectives

  • Discuss clinical presentation and diagnosis of BPDCN.
  • Review PVEK mechanism of action.
  • Review clinical data supporting the approval of PVEK, including efficacy and key safety considerations.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.

Course summary

Course opens: 
11/19/2026
Course expires: 
12/10/2026
Event starts: 
12/10/2026 - 12:00pm EST
Event ends: 
12/10/2026 - 1:00pm EST
Cost:
$0.00

Speaker:

Dr. Eunice Wang
Chief of Leukemia Service
Roswell Park Comprehensive Cancer Center

Price

Cost:
$0.00
Please login or register to take this course.

By registering for this event, you agree not to use any form of artificial intelligence (AI) technology to record, transcribe, or reproduce educational sessions, presentations, or discussions in any format.

Click here for more information on AMCP membership or email memberservices@amcp.org.

Required Hardware/software

AMCP Learn utilizes the Zoom Webinars platform for live webinars. For a smoother experience joining the webinar, please install the Zoom desktop client or mobile app prior to the start time. If you experience technical issues joining the webinar, please email webinars@amcp.org.